Effluent volume and dialysis dose in CRRT: Time for reappraisal

Nature Reviews Nephrology

Volumn 8, Issue 1, 2012, Pages 57-60

  MacEdo, Etienne ^a   Claure Del Granado, Rolando ^b   Mehta, Ravindra L ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Universidad del Valle   (Bolivia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DIALYSIS; DIALYSIS DOSE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; HUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; DIALYSIS SOLUTIONS; HUMANS; RENAL DIALYSIS;

EID: 84455208256     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.172     Document Type: Review

References (30)

1. Ronco, C. et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356, 26-30 (2000). (Pubitemid 30416991)
2. Schiffl, H., Lang, S. M. & Fischer, R. Daily hemodialysis and the outcome of acute renal failure. N. Engl. J. Med. 346, 305-310 (2002). (Pubitemid 34438837)
3. Bouman, C. S., Oudemans-Van Straaten, H. M., Tijssen, J. G., Zandstra, D. F. & Kesecioglu, J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit. Care Med. 30, 2205-2211 (2002). (Pubitemid 35191568)
4. Saudan, P. et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 70, 1312-1317 (2006). (Pubitemid 44435183)
5. Tolwani, A. J. et al. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J. Am. Soc. Nephrol. 19, 1233-1238 (2008).
6. Palevsky, P. M. et al. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 359, 7-20 (2008). (Pubitemid 351931092)
7. Bellomo, R. et al. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 361, 1627-1638 (2009).
8. Ronco, C. et al. Dialysis dose in acute kidney injury: no time for therapeutic nihilism-a critical appraisal of the Acute Renal Failure Trial Network study. Crit. Care 12, 308 (2008).
9. Marshall, M. R. Current status of dosing and quantification of acute renal replacement therapy. Part 1: mechanisms and consequences of therapy under-delivery. Nephrology (Carlton) 11, 171-180 (2006). (Pubitemid 43832925)
10. Feldhoff, P., Turnham, T. & Klein, E. Effect of plasma proteins on the sieving spectra of hemofilters. Artif. Organs 8, 186-192 (1984). (Pubitemid 14121536)
11. Brunet, S. et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am. J. Kidney Dis. 34, 486-492 (1999). (Pubitemid 29413621)
12. Granado, R. C. et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis. Clin. J. Am. Soc. Nephrol. 6, 467-475 (2011).
13. Clark, W. R., Turk, J. E., Kraus, M. A. & Gao, D. Dose determinants in continuous renal replacement therapy. Artif. Organs 27, 815-820 (2003). (Pubitemid 37108622)
14. Claure-Del Granado, R. et al. Effect of type of anticoagulation on delivered dialysis dose of CRRT abstract. American Society of Nephrology Renal Week TH-PO422 (2010).
15. Evanson, J. A. et al. Prescribed versus delivered dialysis in acute renal failure patients. Am. J. Kidney Dis. 32, 731-738 (1998). (Pubitemid 28516302)
16. Vesconi, S. et al. and the DOse REsponse Multicentre International collaborative Initiative (DO-RE-MI Study Group). Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit. Care 13, R57 (2009).
17. Venkataraman, R., Kellum, J. A. & Palevsky, P. Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. J. Crit. Care 17, 246-250 (2002). (Pubitemid 35447400)
18. Goldstein, S. L. et al. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 107, 1309-1312 (2001). (Pubitemid 32525207)
19. Bouchard, J. et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 76, 422-427 (2009).
20. Bouchard, J., Macedo, E. & Mehta, R. L. Dosing of renal replacement therapy in acute kidney injury: lessons learned from clinical trials. Am. J. Kidney Dis. 55, 570-579 (2010).
21. Fukuma, S. et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the Dialysis Registry in Japan. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd. 2011.07.014.
22. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
23. Phrommintikul, A., Haas, S. J., Elsik, M. & Krum, H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369, 381-388 (2007). (Pubitemid 46188479)
24. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).
25. Ma, J. Z., Ebben, J., Xia, H. & Collins, A. J. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol. 10, 610-619 (1999). (Pubitemid 29117643)
26. Zhang, Y., Thamer, M., Stefanik, K., Kaufman, J. & Cotter, D. J. Epoetin requirements predict mortality in hemodialysis patients. Am. J. Kidney Dis. 44, 866-876 (2004). (Pubitemid 39445919)
27. Macdougall, I. C. Recent advances in erythropoietic agents in renal anemia. Semin. Nephrol. 26, 313-318 (2006).
28. Strippoli, G. F. et al. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C. E. DOSE) trial protocol. Trials 11, 70 (2010).
29. Fishbane, S. Recombinant human erythropoietin: has treatment reached its full potential? Semin. Dial. 19, 1-4 (2006). (Pubitemid 43479005)
30. US Department of Health & Human Services. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. US Food and Drug Administration online, http://www.fda.gov/Drugs/DrugSafety/ucm259639. htm (2011).